SecBot SecBot
PRESS-RELEASE ·Filed Jun 29, 2026

ABVX

Abivax
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The positive Part 2 results materially improve the risk/reward for obefazimod's NDA submission in Q4 2026. Traders should monitor for FDA acceptance and potential advisory committee meeting.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$133.26
T+0 close · Jun 29, 2026 · via day close
Latest settled
−29.36%
T+60 · $94.13
Vs SPY
−32.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $133.26entry
  2. T+1 · 5mo ago −0.53%α −0.39% · $132.56
  3. T+5 · 4mo ago +8.05%α +7.45% · $143.99
  4. T+20 · 4mo ago −3.95%α −2.92% · $128.00
  5. T+60 · 8w ago −29.36%α −32.18% · $94.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission in induction non-responders and 45.5% recapture of remission in relapsers. The expanded safety database (1,704 patient-years) showed malignancy rates consistent with UC background rates. The company remains on track for NDA submission in Q4 2026.

Key Facts

  • 37.2% of induction non-responders achieved clinical remission at Week 44 on 50 mg obefazimod
  • 45.5% of patients who relapsed on 25 mg and escalated to 50 mg recaptured clinical remission
  • Exposure-adjusted malignancy rates (excluding NMSC) were 0.35 per 100 PY in all-active combined, within UC background range of 0.30–0.70
  • NDA submission for obefazimod in UC remains on track for Q4 2026
  • Integrated safety database includes 1,704 patient-years of exposure across Phase 2 and Phase 3 programs

Financial Impact

Positive Phase 3 maintenance data strengthens NDA package and de-risks approval path for obefazimod, a potential blockbuster UC therapy. Stock price reaction likely significant given prior safety concerns are addressed with expanded dataset.

pipeline valueprobability of regulatory approvalpeak sales estimates

Risk Factors

  • FDA may still issue a Complete Response Letter (CRL) despite expanded safety data
  • Competition from existing and emerging UC therapies (JAK inhibitors, IL-23 blockers) could limit commercial uptake
  • Long-term safety monitoring continues; any new signal could derail approval

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3319283

Track record

10 reports on ABVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Viewing Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (12h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026